Floatz logo

AEX4089DC1

Androgen-Independent Prostatic Cancer

MacroGenicsantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Androgen-Independent Prostatic Cancer cohort.

Asset / SponsorPhaseRating
Lorigerlimab
MacroGenics
Phase 2BB

Same molecule, other indications

AEX4089DC1 is also rated in:

small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Anal NeoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
Carcinoma, Squamous Cell of Head and NeckDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →